Abiopharma

🔍 Wilkes Alexander (Director)

Company: National Vision Holdings, Inc. (EYE)

Report Date: 2026-07-31

Detailed Transactions and Holdings:

• Acquired 13,768 shares of Common Stock (Direct)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,199.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,660 shares of Common Stock at $22.04 per share (Direct)
  Date: 2026-07-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 23,539.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 13,768 shares of Restricted Stock Units (Derivative)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 268,660.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: Includes 1,917 shares acquired under the 2018 Associate Stock Purchase Plan.
• F3: Reflects payment of tax liability by withholding securities incident to vesting of restricted stock units.
• F4: On August 1, 2025, the reporting person was granted 41,306 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.